Abstract
Bioresorbable vascular scaffolds (BVS) have become an attractive option in the percutaneous coronary intervention field due to the potential advantages associated with the complete resorption process that occurs within a few years. However, current-generation BVS have several limitations including thicker struts, reduced radial strength, and limited expansion capability when compared with drug-eluting stents (DES). As a result, complex coronary disease often contains BVS-inappropriate/unfavorable segments. This does not necessarily mean that BVS use must be completely avoided, and minimizing the length of permanent metallic caging may still be advantageous. Operators should fully understand the limitations of current BVS, and when to consider a hybrid strategy of BVS in combination with DES or drug-coated balloons.
Original language | English (US) |
---|---|
Pages (from-to) | 539-547 |
Number of pages | 9 |
Journal | JACC: Cardiovascular Interventions |
Volume | 10 |
Issue number | 6 |
DOIs | |
State | Published - Mar 27 2017 |
Externally published | Yes |
Keywords
- bioresorbable scaffold
- drug-coated balloon
- drug-eluting stent(s)
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine